ReviewInternational journal of molecular sciences2023

The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.

Kenji NakanoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.